Get the Stockscreener App
111.16
1.73%
1.89
After Hours:
111.50
0.34
+0.31%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $111.16, with a volume of 6.04M.
It is up +1.73% in the last 24 hours and down -0.74% over the past month.
See More
Previous Close:
$109.27
Open:
$110
24h Volume:
6.04M
Relative Volume:
0.80
Market Cap:
$138.43B
Revenue:
$28.75B
Net Income/Loss:
$480.00M
P/E Ratio:
300.43
EPS:
0.37
Net Cash Flow:
$10.31B
1W Performance:
+5.00%
1M Performance:
-0.74%
6M Performance:
+32.95%
1Y Performance:
+52.25%
1-Day Range:
$109.73
$111.81
1-Week Range:
$104.92
$111.81
52-Week Range:
$62.07
$119.96
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
111.16 | 138.43B | 28.75B | 480.00M | 10.31B | 0.37 |
|
LLY
Lilly Eli Co
|
821.67 | 738.00B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
202.72 | 358.61B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
163.13 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
70.16 | 311.44B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
87.60 | 221.28B | 64.17B | 17.12B | 18.10B | 6.73 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Gilead Sciences CEO's pay climbed to $23.7 millionSan Francisco Business Times - The Business Journals
Gilead Says CEO Daniel O'Day's 2024 Total Compensation Was $23.7 MillionSEC Filing - Marketscreener.com
What Analysts Are Saying About Gilead Sciences Stock - Benzinga
A Closer Look at Gilead Sciences's Options Market Dynamics - Benzinga
JPMorgan Adjusts Price Target on Gilead Sciences to $130 From $120, Maintains Overweight Rating - Marketscreener.com
Potential federal budget cuts won't rock Gilead's HIV boat too much: analysts - FiercePharma
Gilead’s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise. - Barron's
Are Medical Stocks Lagging Gilead Sciences (GILD) This Year? - Yahoo Finance
Gilead price tries to regain footingForecast today26-03-2025 - Economies.com
Former Gilead Sciences VP Named CEO as Biomea Advances Breakthrough Diabetes Drug - StockTitan
Gilead, J&J Sue Laurus Labs to Block Copy of HIV Drug Complera - Bloomberg Law
Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer - ACCESS Newswire
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
The Inner Circle acknowledges, Christopher McCormick as a Pinnacle Professional Member Inner Circle of Excellence - Yahoo Finance
Gilead Sees Success With HIV PrEP Trial In South Africa - Clinical Leader
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval - Seeking Alpha
Gilead Sciences Inc (GILD) Shares Up 1.14% on Mar 22 - GuruFocus.com
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences Inc (GILD) - GuruFocus.com
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed - Benzinga
Gilead Sciences Inc (GILD) Stock Price Up 0.52% on Mar 21 - GuruFocus.com
Gilead Sciences stock performance analysis: A rare Nasdaq gem with consistent returns across time horizons - The Financial Express
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
GILD Stock Down on Report of Cut in HIV Prevention Spending - Yahoo Finance
Oppenheimer doesn’t see threat to Gilead estimates after HHS plans for HIV cuts - Yahoo Finance
Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed - MSN
Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides - Yahoo Finance
Gilead Stock Falls on Report U.S. Could Slash HIV-Prevention Budget - The Wall Street Journal
Gilead stock falls on report of HIV prevention cuts - Yahoo Finance
Gilead Stock Dives On A Devastating Potential Call From HHS - Investor's Business Daily
Stock of the Day: Gilead Sciences falls on report the Trump administration could slash funds for HIV prevention - Yahoo Finance
Wall Street weighs in on Gilead as shares fall on possible U.S. HIV cuts - Investing.com Canada
BMO reiterates Gilead stock with $115 target amid HIV funding concerns - Investing.com
Citi maintains Gilead stock Buy rating, $125 target amid HIV funding fears - Investing.com
Gilead Sciences Should Not See Any Impact From HIV-Related Cost Reductions at US Healthcare Department, Truist Says - Marketscreener.com
Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies - CSRwire.com
Gilead Sciences’ SWOT analysis: HIV giant’s stock faces pivotal transition - Investing.com
Gilead Sciences Stock Slips on Possible HIV Funding Cut - Schaeffers Research
Why Gilead Sciences (GILD) Is Among the Most Undervalued Biotech Stocks to Invest In - Insider Monkey
Citi Defending Gilead Sciences (GILD): 'we are buyers of GILD stock on any weakness ahead of the upcoming Len PrEP launch in mid-2025' - StreetInsider.com
Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention Funding - Barron's
Gilead Stock (NYSE:GILD) Slumps on HIV Funding Cuts Report - TipRanks
Gilead slides as Trump administration puts HIV prevention funds under review - TradingView
Gilead Sciences (GILD): Potential Impact of Federal HIV Funding Cuts - Value the Markets
Gilead, GSK could be impacted by potential HHS HIV prevention cuts - Seeking Alpha
Gilead Sciences CFO Andrew Dickinson sells $276,325 in stock - Investing.com
After-hours movers: Gilead Sciences, HealthEquity, CARGO Therapeutics and more - Investing.com
Gilead Sciences stock falls on potential HIV funding cuts By Investing.com - Investing.com Australia
Gilead Sciences stock falls on potential HIV funding cuts - Investing.com
Unpacking the Latest Options Trading Trends in Gilead Sciences - Benzinga
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.75%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):